Other novel agents: Rationale and current status as chemopreventive agents

Urology

Volumn 57, Issue 4, 2001, Pages 86-89

  Tolcher, Anthony W ^a   Kennedy, Ann ^b   Padley, Rober J ^c   Majeed, Noreen ^d   Pollak, Michael ^e   Kantoff, Philip W ^e  

^a CTRC Institute for Drug Development   (United States)

^b Philadelphia Pennsylvania ^*  (United States)

^c ABBOTT LABORATORIES   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOWMAN BIRK INHIBITOR; DNA; ENDOTHELIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN; SUPEROXIDE; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; CANCER CENTER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DNA DAMAGE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

ANTICARCINOGENIC AGENTS; CHROMANS; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; SOMATOMEDINS; THIAZOLES; THIAZOLIDINEDIONES; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 0034973651     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00948-1     Document Type: Article

References (41)

1. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent
2. Chemopreventive agents: Protease inhibitors
3. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells
4. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor
5. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate
6. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray induced transformation in vitro
7. Distribution of the Bowman Birk protease inhibitor in mice following oral administration
8. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
9. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines
10. Growth regulatory properties of endothelins
11. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer
12. Endothelins
13. Endothelin antagonists
14. Endothelin-1-induced nociception
15. ABT-627, endothelin-receptor antagonist, for advanced cancer: Phase I and pharmacokinetic results
16. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
17. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
18. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
19. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells
20. Differentiation and reversal of malignant changes in colon cancer through PPARgamma
21. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
22. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
23. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
24. Troglitazone-induced hepatic failure leading to liver transplantation: A case report
25. The IGF-I receptor and cancer
26. Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases
27. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
28. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
29. Insulin-like growth factor-I and prostate cancer risk: A population-based, case-control study
30. Hormonal predictors of prostate cancer: A meta-analysis
31. Insulin-like growth factors and prostate cancer
32. The potential role of somatostatin analogues in breast cancer treatment
33. Treatment of acromegaly with the growth hormone-receptor antagonist Pegvisomant
34. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
35. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
36. Bicalutimide (casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins
37. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5
38. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3
39. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
40. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089
41. Antiproliferative effects of vitamin d-related compounds and insulin-like growth factor binding protein 5 accumulation